Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 243 results:
Συντάκτης [ Τίτλος(Desc)] Τύπος Έτος
Φίλτρα: Συντάκτης is Karagiannis, Asterios  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Athyros, V. G., Mitsiou E. K., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Concurrent blood pressure, glycemic and lipid control for the prevention of vascular complications of type II diabetes mellitus: a long overdue objective?. Curr Vasc Pharmacol. 8(1), 1-4.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2015).  Contrast-Induced Nephropathy: An "All or None" Phenomenon?. Angiology. 66(6), 508-13.
Athyros, V. G., Kakafika A. I., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2008).  CORONA, statins, and heart failure: who lost the crown?. Angiology. 59(1), 5-8.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2011).  Current treatment for nonalcoholic fatty liver disease.. Expert Opin Pharmacother. 12(13), 2141-2; author reply 2142.
D
Papadopoulou, E., Loutradis C., Tzatzagou G., Kotsa K., Zografou I., Minopoulou I., et al. (2020).  Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial.. J Hypertens.
Papadopoulou, E., Theodorakopoulou M. P., Loutradis C., Tzanis G., Tzatzagou G., Kotsa K., et al. (2021).  Dapagliflozin Does Not Affect Short-Term Blood Pressure Variability in Patients With Type 2 Diabetes Mellitus.. Am J Hypertens. 34(4), 404-413.
Stavropoulos, K., Imprialos K. P., Faselis C., Karagiannis A., & Papademetriou V. (2019).  Determinants of pulse wave velocity index and potential implementations.. J Clin Hypertens (Greenwich).
Athyros, V. G., Doumas M., Imprialos K. P., Stavropoulos K., Georgianou E., Katsimardou A., et al. (2018).  Diabetes and lipid metabolism.. Hormones (Athens). 17(1), 61-67.
Anagnostis, P., Paschou S. A., Goulis D. G., Athyros V. G., & Karagiannis A. (2018).  Dietary management of dyslipidaemias. Is there any evidence for cardiovascular benefit?. Maturitas. 108, 45-52.
Athyros, V. Gabriel, Doumas M., & Karagiannis A. (2016).  Differential residual dyslipidemia/cardiovascular risk after statin treatment between Asian-Indians and western whites. Call for action.. Indian Heart J. 68(5), 596-598.
Athyros, V. G., Tziomalos K., Mikhailidis D. P., Pagourelias E. D., Kakafika A. I., Skaperdas A., et al. (2007).  Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?. Expert Opin Pharmacother. 8(14), 2267-77.
Athyros, V. G., Kakafika A. I., Karagiannis A., & Mikhailidis D. P. (2008).  Do we need to consider inflammatory markers when we treat atherosclerotic disease?. Atherosclerosis. 200(1), 1-12.
Karagiannis, A., Mathiopoulou L., Tziomalos K., Kontotasios K., Skaperdas A., Florentin M., et al. (2006).  Dry cough as first manifestation of giant-cell arteritis.. J Am Geriatr Soc. 54(12), 1957-8.
Kakafika, A. I., Liberopoulos E. N., Karagiannis A., Athyros V. G., & Mikhailidis D. P. (2006).  Dyslipidaemia, hypercoagulability and the metabolic syndrome.. Curr Vasc Pharmacol. 4(3), 175-83.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2011).  Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment.. Open Cardiovasc Med J. 5, 24-34.
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2009).  Dyslipidemia as a risk factor for ischemic stroke.. Curr Top Med Chem. 9(14), 1291-7.
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2011).  Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.. Open Cardiovasc Med J. 5, 85-9.
E
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?. Curr Vasc Pharmacol. 14(6), 494-497.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Editorial: Cardiovascular Disease Mortality Rates are Plateauing in Certain Age Groups and Regions. Can we Keep them Declining?. Curr Vasc Pharmacol. 14(3), 271-4.
Athyros, V. G., Katsiki N., Karagiannis A., & Radak D. (2015).  Editorial: effect of statins on rates of long-term cardiovascular events and restenosis following carotid endarterectomy.. Curr Vasc Pharmacol. 13(2), 223-5.
Athyros, V. G., Katsiki N., & Karagiannis A. (2015).  Editorial: microRNAs: Potential Targets for the Treatment of Cardiovascular Disease.. Curr Vasc Pharmacol. 13(3), 366-7.
Athyros, V. G., Katsiki N., & Karagiannis A. (2014).  Editorial: (New drug (LCZ696) for the treatment of heart failure with reduced ejection fraction after 10 years. Can one study change the guidelines?).. Curr Vasc Pharmacol. 12(6), 867-9.
Athyros, V. G., Katsiki N., & Karagiannis A. (2014).  Editorial: (Persistent elevation of blood pressure in children and adolescents is associated with arterial hypertension and premature atherosclerosis in adults. Is it possible to reverse this?).. Curr Vasc Pharmacol. 12(6), 870-2.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  Editorial: should chronic kidney disease be considered as a coronary heart disease equivalent?. Curr Vasc Pharmacol. 10(3), 374-7.
Athyros, V. G., Tziomalos K., & Karagiannis A. (2015).  Editorial: Statins or Fibrates for the Primary Prevention of Stroke in the Elderly. Faith Makes Some Things Achievable, But Not AII.. Curr Vasc Pharmacol. 13(6), 696-8.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές